NURS617 EXAM 1 Actual Exam 2026/2027 Complete
Questions and Verified Answers with Detailed
Rationales Pharmacotherapeutics Review Grade A
100% Correct Pass Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS (Questions 1-15)
Q1: A 68-year-old patient with atrial fibrillation is started on warfarin. The NP understands that
warfarin's anticoagulant effect is monitored using which laboratory value, and what is the
therapeutic range for most indications?
A. aPTT; 1.5-2.5 times control
B. INR; 2.0-3.0. [CORRECT]
C. Anti-Xa; 0.5-1.0 IU/mL
D. Bleeding time; 3-9 minutes
Correct Answer: B
Rationale: Warfarin's anticoagulant effect is monitored using the International Normalized Ratio
(INR). For most indications, including atrial fibrillation and venous thromboembolism, the
therapeutic target INR is 2.0-3.0 (B). aPTT (A) is used to monitor unfractionated heparin. Anti-
Xa (C) is used to monitor LMWH. Bleeding time (D) is not used to monitor warfarin.
Q2: A patient taking carbamazepine for epilepsy has breakthrough seizures after starting a new
medication for a fungal infection. Which antifungal agent most likely caused this interaction by
inducing hepatic metabolism of carbamazepine?
A. Fluconazole
B. Itraconazole
C. Ketoconazole
D. None of the above; carbamazepine is the enzyme inducer [CORRECT]
Correct Answer: D
Rationale: Carbamazepine is a potent CYP450 enzyme inducer (CYP3A4, CYP2C9), not the
antifungal. Ketoconazole (C), itraconazole (B), and fluconazole (A) are actually CYP3A4
inhibitors that would increase carbamazepine levels. The scenario suggests carbamazepine
induced metabolism of the antifungal or another drug, or the question tests knowledge that
carbamazepine is the inducer. If seizure breakthrough occurred, it may be due to reduced
carbamazepine levels from auto-induction or drug interactions.
,Q3: A patient with liver cirrhosis is prescribed a medication that undergoes extensive first-pass
metabolism. What change in pharmacokinetics should the NP anticipate?
A. Increased bioavailability due to reduced hepatic extraction [CORRECT]
B. Decreased bioavailability due to portal hypertension
C. No change in bioavailability
D. Increased clearance through alternative pathways
Correct Answer: A
Rationale: In liver cirrhosis, hepatic blood flow is reduced and hepatocellular function is
impaired, leading to decreased first-pass metabolism. This results in increased bioavailability of
drugs with high extraction ratios (A). Portal hypertension (B) does not decrease bioavailability.
Clearance (D) is typically reduced, not increased.
Q4: A patient is prescribed a drug with a therapeutic index of 2. The NP recognizes this
indicates:
A. A very safe drug with a wide margin of safety
B. A drug requiring careful monitoring due to narrow therapeutic window [CORRECT]
C. A drug with no toxicity at any dose
D. A drug that is ineffective at standard doses
Correct Answer: B
Rationale: The therapeutic index (TI) is calculated as TD50/ED50. A TI of 2 indicates that the
toxic dose is only twice the effective dose, representing a narrow therapeutic window requiring
careful monitoring (B). A wide margin of safety (A) would be indicated by a much higher TI
(e.g., >100).
Q5: A patient taking phenytoin for seizures is found to have subtherapeutic drug levels despite
good adherence. The patient recently started taking St. John's wort for depression. What is the
most likely mechanism?
A. St. John's wort inhibits CYP2C9, increasing phenytoin metabolism
B. St. John's wort induces CYP3A4 and P-glycoprotein, reducing phenytoin absorption and
metabolism [CORRECT]
C. St. John's wort displaces phenytoin from protein binding sites
D. St. John's wort inhibits phenytoin renal excretion
Correct Answer: B
Rationale: St. John's wort is a potent inducer of CYP3A4 and P-glycoprotein, which can reduce
, bioavailability and increase metabolism of substrates like phenytoin (B). It does not inhibit
CYP2C9 (A) or renal excretion (D). Protein binding displacement (C) would transiently increase
free drug, not reduce total levels.
Q6: A patient with G6PD deficiency develops hemolytic anemia after taking a prescribed
medication. Which drug class is most likely responsible?
A. Beta-lactam antibiotics
B. Sulfonamides or antimalarials [CORRECT]
C. Statins
D. ACE inhibitors
Correct Answer: B
Rationale: G6PD deficiency causes red blood cells to be vulnerable to oxidative stress. Drugs
that cause oxidative stress, including sulfonamides, antimalarials (primaquine), dapsone, and
nitrofurantoin, can trigger hemolytic anemia in these patients (B). Beta-lactams (A), statins (C),
and ACE inhibitors (D) are not typically associated with G6PD-related hemolysis.
Q7: A patient is prescribed codeine for postoperative pain but reports no analgesic effect.
Genetic testing reveals CYP2D6 poor metabolizer status. What is the pharmacological
explanation?
A. Codeine is a prodrug requiring CYP2D6 conversion to morphine [CORRECT]
B. CYP2D6 poor metabolizers rapidly clear codeine
C. Codeine is metabolized to toxic metabolites by CYP2D6
D. CYP2D6 is required for codeine renal excretion
Correct Answer: A
Rationale: Codeine is a prodrug that requires metabolism by CYP2D6 to its active metabolite,
morphine, for analgesic effect. Poor metabolizers cannot effectively convert codeine to
morphine, resulting in therapeutic failure (A). Rapid clearance (B) would occur in ultrarapid
metabolizers. Codeine does not produce toxic metabolites via CYP2D6 (C).
Q8: A patient on chronic prednisone therapy for rheumatoid arthritis is advised to take the
medication in the morning. The rationale for this timing is:
A. To minimize hypothalamic-pituitary-adrenal axis suppression [CORRECT]
B. To enhance drug absorption
C. To reduce gastrointestinal side effects
D. To increase renal clearance
Questions and Verified Answers with Detailed
Rationales Pharmacotherapeutics Review Grade A
100% Correct Pass Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS (Questions 1-15)
Q1: A 68-year-old patient with atrial fibrillation is started on warfarin. The NP understands that
warfarin's anticoagulant effect is monitored using which laboratory value, and what is the
therapeutic range for most indications?
A. aPTT; 1.5-2.5 times control
B. INR; 2.0-3.0. [CORRECT]
C. Anti-Xa; 0.5-1.0 IU/mL
D. Bleeding time; 3-9 minutes
Correct Answer: B
Rationale: Warfarin's anticoagulant effect is monitored using the International Normalized Ratio
(INR). For most indications, including atrial fibrillation and venous thromboembolism, the
therapeutic target INR is 2.0-3.0 (B). aPTT (A) is used to monitor unfractionated heparin. Anti-
Xa (C) is used to monitor LMWH. Bleeding time (D) is not used to monitor warfarin.
Q2: A patient taking carbamazepine for epilepsy has breakthrough seizures after starting a new
medication for a fungal infection. Which antifungal agent most likely caused this interaction by
inducing hepatic metabolism of carbamazepine?
A. Fluconazole
B. Itraconazole
C. Ketoconazole
D. None of the above; carbamazepine is the enzyme inducer [CORRECT]
Correct Answer: D
Rationale: Carbamazepine is a potent CYP450 enzyme inducer (CYP3A4, CYP2C9), not the
antifungal. Ketoconazole (C), itraconazole (B), and fluconazole (A) are actually CYP3A4
inhibitors that would increase carbamazepine levels. The scenario suggests carbamazepine
induced metabolism of the antifungal or another drug, or the question tests knowledge that
carbamazepine is the inducer. If seizure breakthrough occurred, it may be due to reduced
carbamazepine levels from auto-induction or drug interactions.
,Q3: A patient with liver cirrhosis is prescribed a medication that undergoes extensive first-pass
metabolism. What change in pharmacokinetics should the NP anticipate?
A. Increased bioavailability due to reduced hepatic extraction [CORRECT]
B. Decreased bioavailability due to portal hypertension
C. No change in bioavailability
D. Increased clearance through alternative pathways
Correct Answer: A
Rationale: In liver cirrhosis, hepatic blood flow is reduced and hepatocellular function is
impaired, leading to decreased first-pass metabolism. This results in increased bioavailability of
drugs with high extraction ratios (A). Portal hypertension (B) does not decrease bioavailability.
Clearance (D) is typically reduced, not increased.
Q4: A patient is prescribed a drug with a therapeutic index of 2. The NP recognizes this
indicates:
A. A very safe drug with a wide margin of safety
B. A drug requiring careful monitoring due to narrow therapeutic window [CORRECT]
C. A drug with no toxicity at any dose
D. A drug that is ineffective at standard doses
Correct Answer: B
Rationale: The therapeutic index (TI) is calculated as TD50/ED50. A TI of 2 indicates that the
toxic dose is only twice the effective dose, representing a narrow therapeutic window requiring
careful monitoring (B). A wide margin of safety (A) would be indicated by a much higher TI
(e.g., >100).
Q5: A patient taking phenytoin for seizures is found to have subtherapeutic drug levels despite
good adherence. The patient recently started taking St. John's wort for depression. What is the
most likely mechanism?
A. St. John's wort inhibits CYP2C9, increasing phenytoin metabolism
B. St. John's wort induces CYP3A4 and P-glycoprotein, reducing phenytoin absorption and
metabolism [CORRECT]
C. St. John's wort displaces phenytoin from protein binding sites
D. St. John's wort inhibits phenytoin renal excretion
Correct Answer: B
Rationale: St. John's wort is a potent inducer of CYP3A4 and P-glycoprotein, which can reduce
, bioavailability and increase metabolism of substrates like phenytoin (B). It does not inhibit
CYP2C9 (A) or renal excretion (D). Protein binding displacement (C) would transiently increase
free drug, not reduce total levels.
Q6: A patient with G6PD deficiency develops hemolytic anemia after taking a prescribed
medication. Which drug class is most likely responsible?
A. Beta-lactam antibiotics
B. Sulfonamides or antimalarials [CORRECT]
C. Statins
D. ACE inhibitors
Correct Answer: B
Rationale: G6PD deficiency causes red blood cells to be vulnerable to oxidative stress. Drugs
that cause oxidative stress, including sulfonamides, antimalarials (primaquine), dapsone, and
nitrofurantoin, can trigger hemolytic anemia in these patients (B). Beta-lactams (A), statins (C),
and ACE inhibitors (D) are not typically associated with G6PD-related hemolysis.
Q7: A patient is prescribed codeine for postoperative pain but reports no analgesic effect.
Genetic testing reveals CYP2D6 poor metabolizer status. What is the pharmacological
explanation?
A. Codeine is a prodrug requiring CYP2D6 conversion to morphine [CORRECT]
B. CYP2D6 poor metabolizers rapidly clear codeine
C. Codeine is metabolized to toxic metabolites by CYP2D6
D. CYP2D6 is required for codeine renal excretion
Correct Answer: A
Rationale: Codeine is a prodrug that requires metabolism by CYP2D6 to its active metabolite,
morphine, for analgesic effect. Poor metabolizers cannot effectively convert codeine to
morphine, resulting in therapeutic failure (A). Rapid clearance (B) would occur in ultrarapid
metabolizers. Codeine does not produce toxic metabolites via CYP2D6 (C).
Q8: A patient on chronic prednisone therapy for rheumatoid arthritis is advised to take the
medication in the morning. The rationale for this timing is:
A. To minimize hypothalamic-pituitary-adrenal axis suppression [CORRECT]
B. To enhance drug absorption
C. To reduce gastrointestinal side effects
D. To increase renal clearance
